Expanding horizons in metastatic NSCLC: unmet need and future directions

Please join us for the AstraZeneca sponsored symposium

Sunday 7th August, 2022 | 13:15–14:15 CET | Hall C7

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15–13:20</td>
<td>Welcome and introduction</td>
<td>Chair: John Heymach</td>
</tr>
<tr>
<td>13:35–13:50</td>
<td>Seeing the unseen: techniques and practical strategies for broad molecular profiling</td>
<td>Elena Guerini-Rocco</td>
</tr>
<tr>
<td>13:50–14:15</td>
<td>Panel discussion and Q&amp;A</td>
<td>All</td>
</tr>
</tbody>
</table>

Dr John Heymach
MD Anderson Cancer Center
Houston, Texas, USA

Prof Niels Reinmuth
Asklepios Lung Clinic
Munich-Gauting, Germany

Dr Elena Guerini-Rocco
University of Milan
Milan, Italy

AstraZeneca's Commitment to Sustainability

- $19 million invested in environmental efficiency projects in 2020 (NRRGG fund)
- 89% of our power is sourced or generated from renewable sources
- 100% of API (Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe
- 20% reduction in our water use since 2015
- 100% of our vehicles will be electric by 2025
- CPD A Lists
  - One of three companies worldwide to achieve double A listing for Climate Change and Water Security for five consecutive years

AstraZeneca is investing up to $1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website.